| Literature DB >> 15001117 |
Abstract
Necrotizing enterocolitis (NEC) is the most common serious, acquired gastrointestinal disorder in the newborn infant. Although many variables are associated with development of NEC, only prematurity has been consistently identified in case-controlled studies. Traditionally, the diving seal reflex has been invoked as the mechanism responsible for ischaemic injury and necrosis. Intestinal ischaemia is likely to be the final common pathway in NEC; however, it is due to the release of vasoconstricting substances, such as platelet activating factor, rather than perinatal asphyxia. Bacteria and/or bacterial toxins are likely to have a key role in the pathogenesis of NEC by fostering production of inflammatory mediators. The role of feeding practices in the pathogenesis of NEC remains controversial. Treatment of infants with NEC generally includes a regimen of bowel rest, gastric decompression, systemic antibiotics and parenteral nutrition. Infants with perforation are generally operated upon; however, there has been recent interest in primary peritoneal drainage as an alternative. Prevention of NEC still remains elusive. Avoidance of preterm birth, use of antenatal steroids and breast-milk feeding are practices that offer the greatest potential benefits. Use of any other strategy should await further trials.Entities:
Mesh:
Year: 2003 PMID: 15001117 PMCID: PMC7128229 DOI: 10.1016/S1084-2756(03)00123-4
Source DB: PubMed Journal: Semin Neonatol ISSN: 1084-2756
Modified Bell staging criteria for necrotizing enterocolitis
| Stage | Classification | System signs | Intestinal signs | Radiological signs |
|---|---|---|---|---|
| IA | Suspected NEC | Temperature instability, apnoea, bradycardia, lethargy | Increased pregavage residuals, mild abdominal distention, emesis, guaiac-positive stool | Normal or intestinal dilation, mild ileus |
| IB | Suspected NEC | Same as above | Bright-red blood from rectum | Same as above |
| IIA | Proven NEC—mildly ill | Same as above | Same as above, plus absent bowel sounds, with or without abdominal tenderness | Intestinal dilation, ileus, pneumatosis intestinalis |
| IIB | Proven NEC—moderately ill | Same as above, plus mild metabolic acidosis and mild thrombocytopenia | Same as above, plus absent bowel sounds, definite abdominal tenderness, with or without abdominal cellulitis or right lower quadrant mass | Same as IIA, plus portal vein gas, with or without ascites |
| IIIA | Advanced NEC—severely ill, bowel intact | Same as IIB, plus hypotension bradycardia, severe apnoea, combined respiratory and metabolic acidosis, disseminated intravascular coagulation, and neutropenia | Same as above, plus signs of generalized peritonitis, marked tenderness, and distention of abdomen | Same as IIB, plus definite ascites |
| IIIB | Advanced NEC—severely ill, bowel perforated | Same as IIIA | Same as IIIA | Same as IIB, plus pneumoperitoneum |
Modified from Ref. 10.
NEC, necrotizing enterocolitis.
Strategies to prevent necrotizing enterocolitis: probable or proven efficacy
| • Breast feeding |
| • Antenatal steroids |
| • Fluid restriction |
| • Enteral administration of antibiotics |
Potential for development of resistant flora.
Strategies to prevent necrotizing enterocolitis: unproven efficacy or limited data
| • Cautious advancement of feedings |
| • Trophic feeding |
| • Enteral administration of immunoglobulin |
| • Supplemental |
| • Supplementation of feedings with egg phospholipids |
| • Acidification of milk feedings |
| • Administration of probiotics |
Unproven efficacy.
Not efficacious.
Limited data.
Potential effects of selected agents in human milk (HM) on the gastrointestinal tract
| Agent in HM | Epithelial growth | Decreased inflammation | sigA production |
|---|---|---|---|
| EGF | + | ? | − |
| IGF-1 | + | ? | − |
| TGF | + | − | − |
| Erythropoietin | + | ? | − |
| IL-6 | − | ? | + |
| TNF-α | − | − | + |
| IL-10 | − | + | + |
| PAF-AH | − | + | − |
| Lysozyme | − | + | − |
GI, gastrointestinal; sigA, secretory immunoglobulin A; EGF, epithelial growth factor; IGF-1, insulin-like growth factor 1; TGF, transforming growth factor; IL, interleukin; TNF-α, tumour necrosis factor α; PAF-AH, platelet activating factor acetylhydrolase.
Reproduced from Ref. 47, with permission.
Fig. 1Relative risk of confirmed necrotizing enterocolitis in infants randomized to donor human milk vs formula milk. Reproduced from Ref. 50, with permission.
Fig. 2Restricted vs liberal water intake for preventing necrotizing enterocolitis. Modified from Ref. 54.
Fig. 3Enteral antibiotics for preventing necrotizing enterocolitis. Modified from Ref. 55.
Fig. 4Enteral antibiotics for preventing necrotizing-enterocolitis-related deaths. Modified from Ref. 55.